Tests vibegron in middle-aged and older adults with obesity
Tests vibegron against placebo in adults aged 45 to 75 with obesity.
Plain-language title generated from the registry record
Registry title: Vibegron for ENergy Thinking and Resilience in Aging
Key facts
- Where
- Winston-Salem, United StatesSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT06987383, who can take part
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06987383
- Record updated
- 28 October 2026
- Original description
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.Read full original descriptionShow less
Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Inclusion: Obese (BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with a waist circumference >102 cm for men and >88 cm for women).
Exclusion: Prior weight loss procedure (e.g., gastric bypass, sleeve gastrectomy, gastric banding); Regular use of the following: weight loss medications (e.g., Orlistat, Belviq, Contrave, Saxenda, Phentermine, Qsymia); medications or dietary supplements known to alter energy metabolism; adrenergic agonists or beta blockers; Symptoms of urinary retention, incontinence, urgency, and frequency or current use of an antimuscarinic medication to treat overactive bladder; Drug/substance abuse or excessive alcohol use within the past 6 months; Evidence of cognitive impairment; Significant medical illness or organ failure, such as uncontrolled hypertension, advanced kidney disease, liver disease, thyroid disease, or active neoplastic disease; Diagnosis of a neurodegenerative illness (e.g., mild cognitive impairment, dementia, Parkinson's disease, Multiple Sclerosis); History of a clinically significant stroke; Cardiac arrhythmia or an abnormal Electrocardiogram; Uncontrolled diabetes (hemoglobin A1c >7%); Body weight ≥450 pounds; Major depression; Weight gain or loss of ≥5% over the past 6 months; Benign prostate hyperplasia; Contraindication to Vibegron or any of its components; Current participation in another intervention or research study that prohibits co-enrollment.